Compare Oatly Group AB - ADR (OTLY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Twist Bioscience Corp — how do they compare? Oatly Group AB - ADR trades at $12.57 (market cap $432.09M), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is far larger — about 19.5× Oatly Group AB - ADR's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| OTLY | TWST | |
|---|---|---|
Market Cap | $432.09M | $8.42B |
Sector | Consumer Staples | Health |
52-Week High | $18.09 | $153.10 |
52-Week Low | $8.03 | $24.16 |
Enterprise Value | $936.50M | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $13.52, down 3.98% today, with a bullish technical signal supported by a recent golden cross and oversold RSI. Revenue growth improved to $862M in 2025, but net losses persist at -$153M, with negative cash flows. Analysts are mixed with 44% buy ratings, while the company raised its 2026 revenue outlook after Q2 results.
The outlook hinges on Oatly's path to profitability; accelerating revenue and margin improvements offer upside, but high debt and sustained losses pose significant risks. Investors should weigh operational progress against financial instability in a competitive plant-based market.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
